• High-risk acute leukemia

• Relapsed/refractory tumors

• Neuroblastoma & lymphoma

• Severe aplastic anemia

• Thalassemia & HLH

• Patients without matched donor

Chung Shan Medical University Hospital's Pediatric Hematology team, led by Director Kang-Hsi Wu, has established a dedicated pediatric haploidentical hematopoietic stem cell transplantation ward, with parents or first-degree relatives as donors, solving the traditional challenge of finding HLA-matched donors. The team pioneered the world-first combined use of antithymocyte globulin (ATG) plus post-transplant cyclophosphamide (PTCy) for GVHD prophylaxis, and was Asia's first to use defibrotide for veno-occlusive disease. Standardized protocols include pre-transplant SDM matching, individualized care plans, ATG/PTCy GVHD prophylaxis, letermovir CMV prevention, and ruxolitinib for aGVHD. Cumulative 178 BMT cases, 27 pediatric haploidentical transplants (most in Taiwan; 71% of national 38 cases across 6 hospitals). Engraftment 100%, severe GVHD 0%, chronic GVHD 0%, viral infection mortality 0%. Helped Indonesia complete its first two HSCTs; trained 10+ Southeast Asian physicians.

• World-first ATG+PTCy GVHD paper in pediatric haplo BMT

• Asia-first defibrotide for VOD

• World-first haplo BMT for HLH

• Letermovir for CMV, ruxolitinib for aGVHD

• World-first cord MSC for engraftment recovery

• Trains international physicians

• Cumulative 178 BMT cases

• 27 pediatric haploidentical transplants (most in Taiwan)

• 71% of 38 national cases (6 hospitals)

• 9 disease categories transplanted

• Helped Indonesia complete first 2 national HSCTs

• 10+ Southeast Asian physicians trained

• Engraftment rate 100% (world 70-90%)

• Severe aGVHD 0% (world 20-40%)

• Chronic GVHD 0%

• Viral infection mortality 0% (world 10-20%)

• Non-relapse mortality 5% (world 10-20%)

• Median ANC engraftment: 14 days

• CMV reactivation 86.7%, all successfully managed

• EBV reactivation 33.3%; 1 PTLD cured with R-CHOP

• BKV grade 4 cystitis 13.3%, cured with cidofovir

• Fungal infection 53.3%, fully controlled with voriconazole

• 4 BSI cases, no mortality

• 2 VOD cases cured with defibrotide

• Dedicated positive-pressure ward

• Parent donation avoids delays

• Individualized care plans, transparent communication

• Documentary featured (58k views)

• SDM builds trust

• Word-of-mouth referrals

• Multiple SCI papers (Pharmaceuticals, Medicine)

• 170+ citations on cord MSC paper

• 2024 International BMT Conference

• Cited by J Clin Oncol (IF 42.1)

• Multiple invited talks in US/JP/KR

• Trained Indonesia, Southeast Asia physicians

• Sets Taiwan benchmark for pediatric haploidentical BMT

• Multiple medical centers adopt our protocol

• Saves children without HLA-matched donors

• Advances cord MSC, CAR-T cell therapy

• Builds international medical diplomacy